Castle Biosciences Inc. (CSTL)
NASDAQ: CSTLHealth CareMedical SpecialitiesUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CSTL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.03B
- EPS (TTM)
- -$0.64
- Dividend yield
- None
- 52-week range
- 17.72 – 44.28
- Day range
- 32.35 – 33.76
- Volume / Avg
- 373.80K / 402.90K
- Beta
- —
- Shares outstanding
- 30.55M
- Next earnings
- Nov 2, 2026
52-week range
CSTL stock today
Shares of Castle Biosciences (CSTL) finished higher on Oct 8 at $33.71, a gain of 2.15% or $0.71 per share, versus the S&P 500's 0.47% decline. At this level, CSTL sits in the middle of its 52-week range of $17.72 to $44.28: 23.9% below the high, set on Jan 26, 2026 and 90.2% above the low. CSTL is down 13.3% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has gained 42.9%.
Castle Biosciences has posted a net loss over the last twelve months (EPS of -$0.64), so its P/E ratio is not meaningful. Castle Biosciences's next earnings report is expected on Nov 2, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Castle Biosciences
Company profileCastle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Derek J. Maetzold
- Headquarters
- Friendswood, TX
- Employees
- 1,002
- IPO year
- 2019
- Website
- castlebiosciences.com
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$45.11+33.82%
- Strong buy 0
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 2, 2026
- EPS estimate
- $-0.38
Castle Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LMRILumexa Imaging Holdings Inc. | 10.33 | -2.46% | $992.45M | vs CSTL |
| TRUPTrupanion Inc. | 25.82 | +4.83% | $1.13B | vs CSTL |
| FLGTFulgent Genetics Inc. | 20.82 | +1.22% | $572.87M | vs CSTL |
| YDESYD Bio Limited | 5.79 | -1.53% | $410.11M | vs CSTL |
| FRNMFreenome Inc. | 15.81 | -1.37% | $1.70B | vs CSTL |
| PSNLPersonalis Inc. | 16.06 | +0.38% | $1.72B | vs CSTL |
| BDSXBiodesix Inc. | 25.63 | -2.99% | $270.43M | vs CSTL |
| TLSITriSalus Life Sciences Inc. | 4.13 | -2.82% | $254.30M | vs CSTL |
Indexes, lists and sector
Castle Biosciences stock FAQ
What is Castle Biosciences's stock price today?
CSTL last traded at $33.71 as of Oct 8, 4:00 PM EDT, up 2.15% on the day. Prices are delayed at least 15 minutes.
When is Castle Biosciences's next earnings date?
Castle Biosciences is expected to report earnings on Monday, November 2, 2026. Analysts expect EPS of $-0.38.
Who is Castle Biosciences's CEO?
Mr. Derek J. Maetzold is the chief executive officer of Castle Biosciences Inc., which has about 1,002 employees.
What is the CSTL 52-week high?
The 52-week high for CSTL is $44.28 and the 52-week low is $17.72. The stock is currently 23.9% below its high.